Abstract：Objective To investigate the effect of histone deacetylase inhibitor CUDC-101 on the expression of androgen receptor shear variant 7 (AR-V7) in castration-resistant prostate cancer (CRPC), and to provide relevant theoretical reference for clinical practice. Methods From January 2018 to June 2019, the expression of AR-V7 protein in CRPC PC-3, VCaP, 22Rvl, LNCap and other 17 cell lines were detected by immunoblotting, while the highest AR-V7 expression was screened further the study. According to different inhibitors, the cell lines were divided into MG149 group and CUDC-101 group. The two inhibitors were compared to reduce the expression of AR-V7 in CRPC cells. Then according to different preparation methods, the cell lines were divided into using MDV3100 alone group, 30 nmol dose CUDC-101 combined application group, and 300 nmol dose CUDC-101 combined application group. The effects on the expression of AR-V7 in CRPC cells were analyzed. Results CRPC cell line 22Rvl had AR-V7 positive expression, and PC-3, VCaP and LNCap CRPC cell lines did not find AR-V7 positive expression. The positive rate of AR-V7 expression in the CUDC-101 group was lower than that in the MG149 group, and the difference was statistically significant (P ＜ 0.05). The AR-V7 positive expression rate 30, 300 nmol dose CUDC-101 combined application group were lower than that in the MDV3100 group alone, and the differences were statistically significant (P ＜ 0.05). Conclusion Histone deacetylase inhibitor CUDC-101 can reduce the expression level of AR-V7, while improve the sensitivity of endocrine therapy. It has the potential to treat CRPC.
张烨 张璐 刘修恒. 组蛋白去乙酰化酶抑制剂CUDC-101对去势抵抗性前列腺癌AR-V7表达的影响[J]. 中国医药导报, 2020, 17(7): 11-14.
ZHANG Ye ZHANG Lu LIU Xiuheng. Effect of histone deacetylase inhibitor CUDC-101 on expression of AR-V7 in castration-resistant prostate cancer. 中国医药导报, 2020, 17(7): 11-14.
[1] Zhou CK，Check DP，Lortet-Tieulent J，et al. Prostate cancer incidence in 43 populations worldwide： An analysis of time trends overall and by age group [J]. Int J Cancer，2016，138（6）：1388-1400.
[2] 许洪修，白进良.AR-V7在去势抵抗性前列腺癌中的作用[J].现代泌尿外科杂志，2016，21（8）：649-652.
[3] Martinez-Breijo S，Chantada-Abal V，Aller-Rodriguez M，et al. Castration resistance mechanisms in prostate cancer [J]. Arch Esp Urol，2018，71（8）：628-638.
[4] Al-Salama ZT. Apalutamide：A Review in Non-Metastatic Castration-Resistant Prostate Cancer [J]. Drugs，2019，79（14）：1591-1598.
[5] Herrmann K，Bluemel C，Weineisen M，et al. Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy [J]. JNucl Med，2015，56（6）：855-861.
[6] Takayama KI. Splicing Factors Have an Essential Role in Prostate Cancer Progression and Androgen Receptor Signaling [J]. Biomolecules，2019，9（4）：13101-13113.
[7] 徐春梅，张子亦，陈羲，等.组蛋白去乙酰化酶抑制剂抗肿瘤作用研究进展[J].中国现代应用药学，2016，33（4）：509-513.
[8] Sir Alpajaro，Harris J，Evans CP. Non-metastatic castration resistant prostate cancer：a review of current and emerging medical therapies [J]. Prostate Cancer Prostatic Dis，2019，22（1）：16-23.
[9] 曾浩，种铁，贺大林，等.去势抵抗性前列腺癌最新指南解读——暨中国西部专家共识[J].现代泌尿外科杂志，2017，22（2）：85-94.
[10] Chandrasekar T，Yang JC，Gao AC，et al. Mechanisms of resistance in castration-resistant prostate cancer (CRPC)[J]. Transl Androl Urol，2015，4（3）：365-380.
[11] Pu F，Salarian M，Xue S，et al. Prostate-specific membrane antigen targeted protein contrast agents for molecular imaging of prostate cancer by MRI [J]. Nanoscale，2016，8（25）：12668-12682.
[12] Belderbos B，Sieuwerts AM，Hoop EO，et al. Associations between AR-V7 status in circulating tumour cells，circulating tumour cell count and survival in men with metastatic castration-resistant prostate cancer [J]. Eur J Cancer，2019，121（9）：48-54.
[13] 林国伟，谢锦来，李励献，等.AR-V7对前列腺癌激素抵抗敏感时间的预测作用[J].现代医学，2015，43（7）：858-862.
[14] Karantanos T，Evans CP，Tombal B，et al. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level [J]. Eur Urol，2015，67（3）：470-479.
[15] 熊诗诗，吴介恒，韩东晖，等.针对前列腺特异性膜抗原的抗体靶向治疗研究进展[J].细胞与分子免疫学杂志，2017，33（2）：278-282.
[16] Markowski MC，Frick KD，Eshleman JR，et al. Cost-Savings Analysis of AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer Eligible for Treatment With Abiraterone or Enzalutamide [J]. Prostate，2016，76（16）：1484-1490.
[17] 韩雪迪，李囡，林新峰，等.前列腺特异性膜抗原靶向分子探针在前列腺癌诊断及治疗中的应用[J].中国医学影像学杂志，2016，24（10）：790-792.
[18] Bastos DA，Antonarakis ES. CTC-derived AR-V7 detection as a prognostic and predictive biomarker in advanced prostate cancer [J]. Expert Rev Mol Diagn，2018， 18（2）：155-163.
[19] 孔祥辉，黄晓军，吕伯东.AR-v7作为去势抵抗性前列腺癌治疗体液标志物的研究进展[J].中国男科学杂志，2018，32（4）：69-72.
[20] Bryce AH，Antonarakis ES. Androgen receptor splice variant 7 in castration-resistant prostate cancer：Clinical considerations [J]. Int J Urol，2016，23（8）：646-653.
[21] 陈泽昱，董强，柳良仁，等.转移性去势抵抗性前列腺癌临床治疗标志物——雄激素受体剪接变异体7[J].中华男科学杂志，2019，25（2）：172-176.
[22] Mahajan K，Malla P，Lawrence HR，et al. ACK1/TNK2 Regulates Histone H4 Tyr88-phosphorylation and AR Gene Expression in Castration-Resistant Prostate Cancer [J]. Cancer Cell，2017，31（6）：790-803.
[23] 林晨，刘湘鄂，吴天玉，等.康艾注射液辅助化疗联合内分泌治疗中晚期前列腺癌效果分析[J].中外医学研究，2019，17（28）：7-9.
[24] 张碧严，李玉凤，赖芸，等.中药复方PC-SPESⅡ抑制人前列腺癌细胞LNCaP增殖及其对AR，PSA表达的影响[J].中国中药杂志，2015，40（5）：950-956.
2020, Vol. 17 
京公网安备 11010502046598号